Blog
Career Paths in TB Research: Technical and Academic Paths
The Working Group on New TB Vaccines (WGNV) Early Career Researcher Network (ECR Network) recently held the first two virtual discussion sessions in a series on career paths in TB research. Technical/Non-Academic Path On the 15th of February, Dr. Mike Leipold, a Research and Development Scientist at Stanford University, tackled the often-pondered question of “if…
TB Vaccine Modeling: A discussion with Dr. Richard White
Vaccine production, from the product concept to development to licensure to deployment is inherently costly and risky for manufacturers, particularly for vaccines against diseases where the burden lies predominantly in lower- and middle-income countries (LMICs). Thus, vaccine manufacturers frequently prioritize high-income markets that offer higher immediate return on investment. The World Health Organization has been…
New TB vaccines needed to tackle AMR
New TB vaccines needed to tackle AMR shares a collective call to decision-makers to prioritize TB vaccine R&D as a signature piece of global health and antimicrobial resistance (AMR) agendas. The brief, from the TB Vax ARM, draws on the latest research in health and economic modelling to demonstrate how new TB vaccines could significantly help control drug-resistant TB, in a cost-effective and affordable way.
Meet the 2023 TB Vaccine Advocacy Fellows
The WGNV and TB Vax ARM, in collaboration with IAVI, are proud to welcome seven participants for a TB vaccine advocacy fellowship. The fellows, representing affected community members, advocates, and early career researchers from five different countries, have come together for a skill-sharing and co-creation program featuring a lineup of workshops led by advocacy experts from around the world. Over the course of the fellowship, the budding TB vaccine advocates will also join forces to develop a collaborative advocacy campaign that will be launched ahead of World TB Day on 24 March.
Words Matter: a researcher’s obligation to think before speaking.
As a teenager, I always said that I would dedicate my life to something meaningful. No matter how big or small the contribution, I vowed to commit my time and energy toward the betterment of others’ wellbeing. I was unsure of the exact route I would take but I trusted myself to know that I’d…
Looking at the Future of TB Research as an Early Career Researcher
Despite the discovery of the causative agent of tuberculosis (TB) (Mycobacterium tuberculosis) by Robert Koch in 1882, there are still many questions regarding the pathophysiology of TB that remain unanswered—particularly in the differentiation and marked variability between latent (asymptomatic, non-transmissible) and active (symptomatic, transmissible) stages of infection. In 2020 the World Health Organization (WHO) estimated…
TB advocates call on Europe to fulfil commitments for new TB vaccines
As representatives of communities affected by tuberculosis (TB) – including survivors, researchers and civil society organizations – we demand long overdue global investments in the research and development of new TB vaccines commensurate with the disease’s devastating impact. The sixth Global Forum on TB Vaccines will be virtually hosted by Toulouse, France this February 22–25…
Leveraging COVID-19 public-private partnerships for TB vaccine development
The past few years have created a paradigm shift in the way we globally respond to and address communicable diseases. Though we remain in the midst of the COVID-19 pandemic, several novel vaccine candidates have been developed, manufactured, studied, approved, distributed, and administered to millions of individuals around the world in less than one year….
M72/ AS01E Works: Now What?
We recently discussed M72/AS01E and the exciting data suggesting its efficacy in preventing progression of TB disease after people had already been exposed to TB. Today, we will put these findings into context. Some of the excitement regarding this trial stems from the novelty of its findings. Dr. Ann Ginsberg is a TB researcher working…
Landmark Trial for Vaccine M72/AS01E
Today, we will look at a landmark trial reporting the full results of a vaccine called M72/AS01E. This trial sought to answer the question: Can this vaccine decrease the rate of TB disease in adults who have already been exposed to TB1? Pulmonary TB, affects the lungs and is the most common form of the…
Guest posts published on this blog reflect the views of their authors and persons interviewed and do not necessarily reflect the views of the Stop TB Partnership Working Group on New TB Vaccines.